產(chǎn)品名稱

TG 101348 - Fedratinib | SAR 302503

產(chǎn)品貨號

Axon 1588 CAS [936091-26-8] MF C27H36N6O3SMW 524.68 Purity: 99% Soluble in DMSO Description An orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 (JAK2, IC50: ca 3 nM) with potential antineoplastic activity. KEYWORDS:?TG 101348 | supplier | JAK2 inhibitor | Fedratinib | SAR 302503 | TG101348 | SAR302503 | TG-101348 | SAR-302503 | CAS [936091-26-8] | JAK-STAT Pathway | Janus-associated kinase | antineoplastic | hematopoietic stem cell | HSC

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

TG 101348 - Fedratinib | SAR 302503

Based on 265 publications in PubMed 10 10 265

Axon 1588

CAS [936091-26-8]

MF C27H36N6O3S
MW 524.68

Purity: 99%
Soluble in DMSO

TG 101348

Description

An orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 (JAK2, IC50: ca 3 nM) with potential antineoplastic activity.

KEYWORDS:?TG 101348 | supplier | JAK2 inhibitor | Fedratinib | SAR 302503 | TG101348 | SAR302503 | TG-101348 | SAR-302503 | CAS [936091-26-8] | JAK-STAT Pathway | Janus-associated kinase | antineoplastic | hematopoietic stem cell | HSC

A Mullally et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15;17(6):584-96.

G Wernig et al. Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Cancer Cell 2008, 13, 311–320.

List of publications using TG 101348 (Axon 1588) purchased from Axon Medchem

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Epigenetics JAK-STAT EC 2.7.10.2 JAK

JAK2 inhibitor

Chemical name

N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide

Parent CAS No.

[936091-26-8]

產(chǎn)品資料